| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2658d45a8e9c71b9598e2bf83242bab3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24211
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C40B30-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2009-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9db4784f02985555e265b01e9236b131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f4671e3cbdad42a5e72223f9b48ae96
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1eb3691a92d76824d3d9013bb5c18b4 |
| publicationDate |
2011-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2011271356-A1 |
| titleOfInvention |
Hcv entry factor, occludin |
| abstract |
The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9510570-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015113673-A1 |
| priorityDate |
2008-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |